Keywords: Ranbaxy, Femara, Novartis, Breast cancer, Zydus Cadila, Formulations plant, India
Ranbaxy debuts generic Femara in UK, France and Romania; FDA OKs Zydus plant
Article | 26 July 2011
India’s largest drugmaker, Ranbaxy Laboratories (RANB: BO) which is 64% owned by Japan’s Daiichi Sankyo (TYO: 4568), yesterday ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
